|
Unfortunately, in this economy, there is much pressure on "cost / benefit analysis" Other than private care facilities, who can afford indiscriminate use of these very costly treatments without a very sound medical justification. I think the time has come for the drug manufacturers to re-assess their pricing structure, there committments to their share holders and balance that with the current mortality rate. For example, Avastin: $16,000 / month?? I thought there were laws against excessive profiteering but this sort of thing is going to bankrupt the Canadian public healthcare system.
trying hard not to be bitter and twisted,
Al
__________________
Primary care-giver to and advocate for Linda, who passed away April 27, 2006.
|